产品
编 号：F741151
分子式：C20H19Cl2F3N2O3
分子量：463.28
分子式：C20H19Cl2F3N2O3
分子量：463.28
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
结构图
CAS No: 1269826-44-9
产品详情
生物活性：
OSBPL7-IN-1 is an orally active oxysterol binding protein like 7 (OSBPL7) inhibitor. OSBPL7-IN-1 promotes an increase of ABCA1 at the plasma membrane without affecting mRNA expression.
体内研究：
OSBPL7-IN-1 (100?mg/kg; oral gavage; daily; for 28 days) treatment normalizes proteinuria and prevents renal function decline in mouse models of proteinuric kidney disease.Animal Model:Female Balb/c mice induced by Adriamycin (ADR)
Dosage:100?mg/kg
Administration:Oral gavage; daily; for 28 days
Result:Normalized proteinuria, and significantly reduced renal fibrosis and renal functional decline.
体外研究：
OSBPL7-IN-1 (compound G or Cpd G; 1-10?μM) increase plasma membrane ATP-binding cassette transporter (ABCA1) in cultured human podocytes, and significantly increase ABCA1-dependent cholesterol efflux.
OSBPL7-IN-1 is an orally active oxysterol binding protein like 7 (OSBPL7) inhibitor. OSBPL7-IN-1 promotes an increase of ABCA1 at the plasma membrane without affecting mRNA expression.
体内研究：
OSBPL7-IN-1 (100?mg/kg; oral gavage; daily; for 28 days) treatment normalizes proteinuria and prevents renal function decline in mouse models of proteinuric kidney disease.Animal Model:Female Balb/c mice induced by Adriamycin (ADR)
Dosage:100?mg/kg
Administration:Oral gavage; daily; for 28 days
Result:Normalized proteinuria, and significantly reduced renal fibrosis and renal functional decline.
体外研究：
OSBPL7-IN-1 (compound G or Cpd G; 1-10?μM) increase plasma membrane ATP-binding cassette transporter (ABCA1) in cultured human podocytes, and significantly increase ABCA1-dependent cholesterol efflux.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备